Several IL13Rα2-targeting therapies, including chimeric antigen receptor (CAR) T cells targeting IL13Rα2, IL13Rα2-targeted immunotoxins, IL13-expressing virus, anti-IL13Rα2 antibody therapy, and IL13Rα2-targeted tumor vaccine, have been tested in clinical trials and found to be safe (11–14). The gene discussed is IL13RA2; the disease is neoplasm.